Sunday 18 October 2026
Export AVLN’s income statement to Excel — free account
Avalyn Pharma Inc.
AVLN
Insiders bought in the last twelve months.
23.66
0.98
−3.98%
Follow AVLN
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | (43.95%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (102.61%) | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (26.84%) | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (3.26) | |
Free Cash Flow |
— | — | — | (96.53) | |
Capital Expenditures |
— | — | — | (0.59) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (12.61%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Operating CF/Net income |
— | — | — | 1.03 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | (1.02) | |
Capex/Depreciation |
— | — | — | 0.48 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | (3.24) | |
Capex per Share |
0.00 | — | 0.00 | (0.02) | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates